Venture Capital for Swiss Proteomics Leader: Biognosys Raises CHF2.7m in Series A Financing
Biognosys, a Swiss ETH spin-off and pioneer in proteomics, has attracted venture capital from experienced...
Setting up scheduled multiplexed MRM experiments and processing MRM signals is a challenge in proteomics research. Biognosys’ proprietary software mQuest / mProphet, the RT-Kit and MRMbase assays resolve these issues (Reiter L, Rinner O et al. Nature Methods 2011, 8(5):430-435). Until now the company has utilised the software component for internal use only. The increased number of requests from industrial customers and the company’s aim for wide-spread MRM proteomics adoption led to a decision to develop a commercial MRM software product. Biognosys is glad to secure support from M2/Co-Services, a cutting-edge IT technology provider, for the software design and implementation.
For more information please contact Biognosys.
Biognosys, a Swiss ETH spin-off and pioneer in proteomics, has attracted venture capital from experienced...
On 29 September Biognosys is invited to present its iRT concept at the 'Mass Spectrometry...
Biognosys, a leading provider of targeted proteomics solutions, is attending the HUPO Tenth Annual World...